1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Poulsen, S.-A. Watson, A.A. Craik, D.J. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US J.Struct.Biol. JSBIEM 0803 1047-8477 130 142 152 10.1006/jsbi.2000.4267 10940222 Solution structures in aqueous SDS micelles of two amyloid beta peptides of A beta(1-28) mutated at the alpha-secretase cleavage site (K16E, K16F) 2000 10.2210/pdb1bjb/pdb pdb_00001bjb 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 3268.439 AMYLOID BETA-PEPTIDE ABETA [F16], RESIDUES 1-28 K16E 1 man polymer no no DAEFRHDSGYEVHHQELVFFAEDVGSNK DAEFRHDSGYEVHHQELVFFAEDVGSNK A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo sample 9606 Homo sapiens 32644 unidentified database_2 pdbx_database_status pdbx_struct_assembly pdbx_struct_oper_list struct_ref_seq_dif repository Initial release Version format compliance Version format compliance Database references Derived calculations Other 1 0 1998-11-04 1 1 2008-03-24 1 2 2011-07-13 1 3 2021-11-03 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.process_site _struct_ref_seq_dif.details Y BNL 1998-06-23 REL REL THE STRUCTURE WAS DETERMINED FROM 2-DIMENSIONAL NMR DATA ON UNLABELLED PEPTIDE LOW ENERGY, LOW VIOLATIONS 50 14 NOESY TOCSY 5.6 1 atm 296 K REFINEMENT DETAILS CAN BE FOUND IN JOURNAL CITATION ABOVE SIMULATED ANNEALING USING NOE DISTANCE CONSTRAINTS SDS MICELLES (100MM)/D2O, H2O BRUNGER refinement XPLOR structure solution X-PLOR 500 Bruker AMX-500 750 Bruker DRX-750 ASP 1 n 1 ASP 1 A ALA 2 n 2 ALA 2 A GLU 3 n 3 GLU 3 A PHE 4 n 4 PHE 4 A ARG 5 n 5 ARG 5 A HIS 6 n 6 HIS 6 A ASP 7 n 7 ASP 7 A SER 8 n 8 SER 8 A GLY 9 n 9 GLY 9 A TYR 10 n 10 TYR 10 A GLU 11 n 11 GLU 11 A VAL 12 n 12 VAL 12 A HIS 13 n 13 HIS 13 A HIS 14 n 14 HIS 14 A GLN 15 n 15 GLN 15 A GLU 16 n 16 GLU 16 A LEU 17 n 17 LEU 17 A VAL 18 n 18 VAL 18 A PHE 19 n 19 PHE 19 A PHE 20 n 20 PHE 20 A ALA 21 n 21 ALA 21 A GLU 22 n 22 GLU 22 A ASP 23 n 23 ASP 23 A VAL 24 n 24 VAL 24 A GLY 25 n 25 GLY 25 A SER 26 n 26 SER 26 A ASN 27 n 27 ASN 27 A LYS 28 n 28 LYS 28 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 5 -3.04 0.50 120.30 117.26 A A A NE CZ NH2 ARG ARG ARG 5 5 5 N 7 -4.29 0.70 120.80 116.51 A A A CB CG CD2 PHE PHE PHE 19 19 19 N 13 -4.51 0.70 120.80 116.29 A A A CB CG CD2 PHE PHE PHE 19 19 19 N 1 A ALA 2 -86.36 -82.11 1 A GLU 3 -162.97 91.97 1 A PHE 4 -173.87 -15.68 1 A ARG 5 -141.01 45.83 1 A HIS 6 -150.66 -48.54 1 A ASP 7 -150.13 32.25 1 A SER 8 -167.31 41.25 1 A TYR 10 36.29 -146.32 1 A GLU 11 -164.26 7.81 1 A VAL 12 69.61 -42.48 1 A HIS 13 75.48 40.17 1 A SER 26 -170.11 36.47 2 A ALA 2 -82.79 -95.09 2 A GLU 3 -156.34 83.44 2 A PHE 4 -147.95 -62.91 2 A ASP 7 -165.86 35.20 2 A SER 8 -162.37 36.88 2 A HIS 13 76.23 -2.50 3 A GLU 3 -177.67 7.03 3 A ASP 7 -174.39 15.59 3 A SER 8 -147.04 32.99 3 A GLU 11 -172.44 141.72 3 A VAL 12 -143.01 -59.75 3 A HIS 13 65.31 -2.13 3 A HIS 14 -89.60 -97.76 3 A SER 26 -167.77 47.91 4 A ALA 2 -165.74 -62.41 4 A GLU 3 -160.86 7.23 4 A HIS 6 -137.99 -54.32 4 A TYR 10 -59.32 175.24 4 A VAL 12 -138.03 -54.21 4 A HIS 13 78.76 -5.08 4 A HIS 14 -98.26 -98.65 4 A SER 26 -147.84 46.80 5 A PHE 4 -158.26 -26.92 5 A TYR 10 -64.41 -168.71 5 A HIS 13 58.29 7.07 5 A HIS 14 -87.70 -76.19 5 A SER 26 42.52 27.67 5 A ASN 27 -151.25 -70.12 6 A ALA 2 -71.99 -73.36 6 A GLU 3 -172.49 21.32 6 A ASP 7 -176.33 25.80 6 A SER 8 -161.59 45.68 6 A GLU 11 -158.29 21.25 6 A VAL 12 72.49 -34.66 6 A HIS 13 74.86 38.07 6 A HIS 14 -137.56 -79.54 6 A SER 26 -149.07 -84.10 7 A GLU 3 48.04 18.84 7 A SER 8 -176.68 34.40 7 A GLU 11 39.11 106.67 7 A VAL 12 -126.93 -63.77 7 A HIS 13 82.11 7.66 7 A HIS 14 -104.68 -78.16 8 A GLU 3 32.73 32.31 8 A HIS 6 52.88 17.08 8 A ASP 7 127.98 37.67 8 A VAL 12 -153.86 -60.84 8 A HIS 13 74.87 -18.28 8 A ASN 27 72.61 56.12 9 A GLU 3 63.92 101.91 9 A PHE 4 -163.89 -38.92 9 A ASP 7 -141.09 19.92 9 A TYR 10 -60.17 -179.78 9 A VAL 12 -143.55 -54.46 9 A HIS 14 -119.30 -94.07 10 A GLU 3 36.19 32.29 10 A PHE 4 -75.96 24.91 10 A SER 8 62.53 64.82 10 A VAL 12 -129.14 -60.69 10 A HIS 14 -93.81 -88.95 10 A SER 26 -75.63 -93.96 11 A GLU 3 54.81 18.09 11 A ARG 5 -65.47 10.07 11 A ASP 7 -152.19 19.11 11 A VAL 12 -131.33 -62.23 11 A HIS 13 77.30 -22.72 11 A HIS 14 -75.17 -95.90 11 A SER 26 47.09 27.74 12 A ALA 2 -154.49 -107.85 12 A GLU 3 -168.75 27.27 12 A ASP 7 -165.08 35.82 12 A SER 8 -158.56 32.17 12 A VAL 12 -139.16 -50.59 12 A HIS 13 73.73 -7.35 12 A HIS 14 -95.46 -97.63 12 A SER 26 42.09 22.83 13 A GLU 3 38.76 31.61 13 A ARG 5 91.60 56.89 13 A ASP 7 76.68 38.02 13 A SER 8 64.63 75.73 13 A GLU 11 -75.23 26.36 13 A VAL 12 72.59 -58.27 13 A HIS 13 90.41 -5.42 13 A HIS 14 -124.77 -65.86 13 A SER 26 -131.12 -34.50 14 A HIS 6 -131.16 -58.69 14 A SER 8 -170.53 24.69 14 A VAL 12 -127.18 -56.68 14 A HIS 13 89.41 -2.25 14 A HIS 14 -100.90 -98.21 model building X-PLOR refinement X-PLOR phasing X-PLOR SOLUTION NMR STRUCTURE OF AMYLOID BETA[E16], RESIDUES 1-28, 14 STRUCTURES 1 Y N A GLU 16 A GLU 16 HELX_P A VAL 24 A VAL 24 1 1 9 GLYCOPROTEIN GLYCOPROTEIN, AMYLOID BETA-PEPTIDE, ALZHEIMER'S DISEASE A4_HUMAN UNP 1 1 P05067 MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPEL QITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSE KSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEE EADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFF YGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEA KHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITAL QAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQD EVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPV DARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITL VMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN 672 699 1BJB 1 28 P05067 A 1 1 28 1 LYS engineered mutation GLU 16 1BJB A P05067 UNP 687 16 1 P 1